Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...
Small cell lung cancer (SCLC) accounts for about 15% of lung cancer cases and is categorized into limited and extensive stages. Treatment options include radiation, chemotherapy, and immunotherapy ...
With 44,000 new diagnoses each year, non-small cell lung cancer is the second most frequent neoplasm in Italy after breast ...
Among patients with stage IA non-small cell lung cancer, long-term survival was better with lobectomy or segmentectomy vs.
Researchers reveal how MAGE-4 and PTEN loss drive cancer growth, suppress immunity and point to new therapeutic strategies ...
According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune response, and tumor progression, though more research is needed.
The drug, Osimertinib—also known by its brand name Tagrisso and produced by AstraZeneca— which increases survival time post-surgery will now join the list of medicines routinely offered by the NHS ...
Patients with extensive-stage small cell lung cancer (ES-SCLC ... with chemotherapy and continued as adjuvant treatment after surgery. School nurses play an overworked and understaffed role ...